Last reviewed · How we verify
NCT06689696
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
trial testing miLens system in Glaucoma in 86 participants. Completed in 6 January 2026.
1 August 2025
Quick facts
| Lead sponsor | Smartlens, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 86 |
| Start date | 19 February 2025 |
| Primary completion | 1 August 2025 |
| Estimated completion | 6 January 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- miLens system
Conditions studied
- Glaucoma — all drugs for Glaucoma →
- GLAUCOMA 1, OPEN ANGLE, D (Disorder) — all drugs for GLAUCOMA 1, OPEN ANGLE, D (Disorder) →
- Ocular Hypertension — all drugs for Ocular Hypertension →
- Ocular Hypertension (OH) — all drugs for Ocular Hypertension (OH) →
Sponsor
Smartlens, Inc.
Who can join
Adults 22 to 80, any sex, with Glaucoma or GLAUCOMA 1, OPEN ANGLE, D (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants. The main questions it aims to answer are: * Is the contact lens device able to detect patterns in eye pressure that happens naturally between nighttime and daytime? * Are the contact lens recording patterns similar when repeated one week later? * What eye problems do participants have when wearing contact lens for up to 24 hours? Researchers will compare if the recordings detected by the contact lens over 24 hours are similar to the patterns measured by an eye pressure measuring instrument used in a doctor's office. Participants will * Wear contact lens in one eye for up to 24 hours * Take recordings in that eye with smartphone camera every 15 minutes when awake * For those participants who are able to stay overnight at a hotel for the trial, researchers will measure the eye pressure in the other eye every 1 to 2 hours when awake with an eye pressure measuring instrument.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06689696
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma
Currently open trials in the same condition.
- NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
- NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
- NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
- NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
- NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06689696 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Smartlens, Inc.
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689696.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing